Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.6K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Education Research: Choosing Wisely: A Mixed-Methods Study of Career Choices of Students Completing Advanced Neurology Electives.

Neurology. Education·2026
Same author

Neurologic Complications of Cancer and Its Treatment.

Continuum (Minneapolis, Minn.)·2026
Same author

Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy.

Movement disorders clinical practice·2024
Same author

Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2023
Same author

Central Nervous System Infections in Immunocompromised Patients.

Current neurology and neuroscience reports·2021
Same author

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2021
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Nov 19, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K

Neoplastic Myelopathies.

Amy A Pruitt

    Continuum (Minneapolis, Minn.)
    |February 1, 2021
    PubMed
    Summary
    This summary is machine-generated.

    This review covers spinal cord tumor classification and treatment, including new genetic insights and therapies. It highlights the importance of distinguishing tumors from other myelopathies for better patient outcomes.

    More Related Videos

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.3K
    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    10.0K

    Related Experiment Videos

    Last Updated: Nov 19, 2025

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.4K
    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.3K
    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    10.0K

    Area of Science:

    • Neurology
    • Oncology
    • Neurosurgery

    Background:

    • Spinal cord tumors are rare, comprising 2-4% of primary central nervous system tumors.
    • Metastatic disease to the spinal cord is more common than primary tumors.
    • Neoplastic myelopathies encompass diverse pathologies requiring precise diagnosis.

    Purpose of the Study:

    • Review the current classification of primary spinal cord tumors.
    • Explore evolving diagnostic and therapeutic strategies for primary and metastatic spinal cord tumors.
    • Discuss advancements in understanding tumor genetics and novel treatment approaches.

    Main Methods:

    • Review of the 2016 World Health Organization classification system for CNS tumors.
    • Analysis of whole-exome sequencing data for primary glial spinal cord neoplasms.
    • Evaluation of recent advancements in targeted therapies, immunotherapy, and surgical techniques.

    Main Results:

    • The 2016 WHO classification identifies new entities like diffuse midline glioma, H3 K27M mutant.
    • Genetic differences exist between spinal cord and intracranial glial neoplasms, impacting therapy.
    • Novel therapies (targeted, immune checkpoint) offer benefits but can cause complications like enhanced radiation toxicity and paraneoplastic syndromes.

    Conclusions:

    • Accurate diagnosis and classification are crucial for effective spinal cord tumor management.
    • Understanding tumor genetics and biologic behavior guides treatment selection.
    • Integrated approaches using surgery, radiation, and targeted therapies improve outcomes and quality of life.